In subgroup analyses, GLP-1 RA therapy was generally associated with lower risks of hospitalization for coronary artery disease, stroke, heart failure, ESKD, and all-cause mortality compared with sulfonylurea use (Tables S9–S13). This evidence concerns the gene GLP1R and heart failure.